Table 1 Characteristics of the studied population
|  | AAV group (A) (N = 28) | Control group (C) (N = 27) |
|---|---|---|
Age, mean ± SD, years | 58.32 ± 15.14 | 60.3 ± 17.14 |
Sex, females/males (%) | 19 (67.9 %) / 9 (32.1 %) | 18 (66.6 %) / 9 (33.3 %) |
ANCA PR3/MPO | 17 (71 %) / 11 (29 %) | - |
BVAS v3, mean ± SD | 19.14 ± 7.14 | - |
BVAS/WG, mean ± SD | 8.46 ± 3.66 | - |
Organ activity skin joints upper respiratory tract lung kidneys/HD nervous system | 7 (25 %) 24 (86 %) 15 (54 %) 24 (86 %) 21 (75 %) / 12(43 %) 7 (25 %) | - |
Clinical form localized and early systemic generalized severe | 6 (21.4 %) 10 (35.7 %) 12 (42.8 %) | - |
Remission induction glucocorticoids plasmapheresis cyclophosphamide rituximab other | 28 ( 100 %) 7 (25 %) 18( 64 %) 6 ( 21 %) 4 (14 %) | - |